VSVisaSignalOfficial filing intelligence

Employer profile

Crispr Therapeutics

Official filing activity, wage signals, roles, and source freshness in one place.

LCA

12

PERM

0

Median wage

$123,838

Last activity

Mar 31, 2026

Sponsorship signal

Does Crispr Therapeutics sponsor H-1B visas?

Yes — Crispr Therapeutics has a documented H-1B filing history: official US Department of Labor disclosure data lists 12 H-1B labor condition application (LCA) records for this employer. The most recent imported disclosure period is FY2026 Q2.

An LCA is the labor-condition step an employer must file with DOL before USCIS can approve an H-1B petition, so these rows are documented sponsorship activity — not a promise that Crispr Therapeutics will sponsor a new hire, and not evidence that any petition was approved. USCIS decides each petition separately. Verified against official DOL OFLC disclosure data on 2026-08-09.

Green-card signal

Does Crispr Therapeutics file PERM green-card cases?

Not in this dataset — official DOL disclosure data lists no PERM (green-card) records for Crispr Therapeutics, though it does list 12 H-1B labor condition application (LCA) records. The most recent imported disclosure period is FY2026 Q2.

H-1B filing activity without PERM rows is common and is not evidence that Crispr Therapeutics refuses to sponsor green cards: PERM cases are published on their own disclosure calendar, are often filed years after the first H-1B, and appear under whichever legal entity files them. Treat missing PERM rows as an absence of evidence for the imported source periods, not as evidence of absence. Verified against official DOL OFLC PERM disclosure data on 2026-08-09.

Summary

Plain-language read

Crispr Therapeutics has filed 12 Labor Condition Applications (LCA) in FY2026 Q2, with all applications certified. The top roles include Principal Research Associate and Manager, Regulatory Affairs, primarily located in Boston, MA. Salary data indicates a median of $123,838, with a range from $102,000 to $320,000. Notably, there are no PERM applications filed, which may impact long-term employment options. It's important to remember that LCA certification does not guarantee USCIS H-1B petition approval, and PERM certification does not equate to green card approval. This information is not legal advice.

Wondering whether Crispr Therapeutics sponsors H-1B? The H-1B sponsor checker reads any company against the same official LCA and PERM filing signals shown here.

Sources

Imported periods

Employer filing context

Crispr Therapeutics H-1B and PERM research checkpoints

Use this section for searches such as "Crispr Therapeutics H-1B", "Crispr Therapeutics LCA", and "Crispr Therapeutics PERM" before comparing individual case rows.

Activity mix

12 LCA rows and 0 PERM rows are normalized to this employer.

Latest source period: FY2026 Q2.

Search the full LCA & PERM disclosure database to see these rows next to every other employer’s official DOL filings.

Each H-1B petition behind these counts carries government filing fees. See the H-1B sponsor cost breakdown for the per-filing fee stack.

Role and worksite signal

Top observed role: Principal Research Associate. Top worksite: Boston, MA.

See other H-1B sponsors in Massachusetts.

Compare this with the H-1B/LCA and PERM drill-down tabs before treating counts as a hiring signal.

Normalization and source check

82% name match1 aliases

Primary source: DOL OFLC disclosure data. Last verified: . Page updated: .

Name matching is a normalization heuristic. Read the source methodology and import freshness before treating matched aliases as a complete sponsor history.

Filing trends

Crispr Therapeutics H-1B/LCA & PERM filing charts

Server-rendered charts from imported DOL OFLC disclosure data. Filing counts are official signals — not sponsorship, hiring, or approval outcomes.

Imported filings by fiscal year

Crispr Therapeutics shows 12 imported H-1B/LCA and PERM filings in FY2026. Counts are imported DOL filing signals, not sponsorship, hiring, or approval outcomes.

H-1B/LCAPERM
Crispr Therapeutics imported H-1B/LCA and PERM filing counts by fiscal year
Fiscal yearH-1B/LCA filingsPERM filingsTotal filings
FY202612012

Wage distribution (recent imported records)

Crispr Therapeutics imported wage records (n=10) span $102,000 to $320,000, with a middle 50% from $120,000 to $177,480 and a median of $123,838.

Median $123,838

Crispr Therapeutics imported annual wage distribution (US dollars) across recent LCA and PERM records
Minimum$102,000
25th percentile$120,000
Median$123,838
75th percentile$177,480
Maximum$320,000
Records10

Source: DOL OFLC disclosure data, retrieved .

Roles

Top official job titles

Principal Research Associate4
Manager, Regulatory Affairs2
Senior Medical Director, Pharmacovigilance2
Senior Research Associate, Translational Biology2
Associate Clinical Trial Manager1

Worksites

Top locations

Boston, MA12

Status mix

Case statuses

Certified12

Related sponsors

Sponsors adjacent to Crispr Therapeutics

Employers with imported DOL LCA or PERM filings that also list Massachusetts worksites, weighted toward overlapping roles. Shared filing footprints are a research and discovery signal, not a hiring or sponsorship guarantee.

LCA and PERM rows are filing signals, not USCIS approvals, green-card approvals, legal advice, or outcome predictions.

FAQ

Common questions

Does Crispr Therapeutics sponsor H-1B workers?

Yes — Crispr Therapeutics has a documented H-1B filing history: official US Department of Labor disclosure data lists 12 H-1B labor condition application (LCA) records for this employer. The most recent imported disclosure period is FY2026 Q2. An LCA is the labor-condition step an employer must file with DOL before USCIS can approve an H-1B petition, so these rows are documented sponsorship activity — not a promise that Crispr Therapeutics will sponsor a new hire, and not evidence that any petition was approved. USCIS decides each petition separately. Verified against official DOL OFLC disclosure data on 2026-08-09.

Does Crispr Therapeutics file PERM green-card cases?

Not in this dataset — official DOL disclosure data lists no PERM (green-card) records for Crispr Therapeutics, though it does list 12 H-1B labor condition application (LCA) records. The most recent imported disclosure period is FY2026 Q2. H-1B filing activity without PERM rows is common and is not evidence that Crispr Therapeutics refuses to sponsor green cards: PERM cases are published on their own disclosure calendar, are often filed years after the first H-1B, and appear under whichever legal entity files them. Treat missing PERM rows as an absence of evidence for the imported source periods, not as evidence of absence. Verified against official DOL OFLC PERM disclosure data on 2026-08-09.

What does VisaSignal show for Crispr Therapeutics H-1B and PERM?

For Crispr Therapeutics H-1B research, the page summarizes imported DOL LCA labor-condition rows. For Crispr Therapeutics PERM research, it summarizes imported DOL permanent labor certification rows. Both include roles, worksites, wage signals, case-status mix, and the latest source period.

Does an LCA certification mean an H-1B petition was approved?

No. A DOL-certified LCA is not the same as USCIS H-1B petition approval. It is an official labor-condition filing signal that should be interpreted with that limit.

Does a PERM certification mean a green card was approved?

No. PERM certification is one step in an employment-based green card process. It does not mean a green card, I-140 petition, or adjustment of status was approved.

Can this data prove an employer will sponsor a candidate?

No. Official filing history can show recent activity, roles, worksites, and wage signals, but it does not guarantee future sponsorship or predict legal outcomes.